were conducted on I I loosely restrained, conscious dogs which responded with vocalization in a dose-dependent manner to bradykinin (0.6-10 nmol) or acetylcholine (0.1-10 timol) injected into the femoral or the mesenteric artery through a chronically indwelling arterial catheter. Vocalization was taken as being to reflect the algogenic action of these substances. Administration of captopril (1 mg/kg, i.v.) potentiated the algogenic action of bradykinin but not that of acetylcholine injected into either artery. The magnitude of potentiation of the algogenic action was about 3-fold for bradykinin injected into the femoral artery and about 10-fold for that injected into the mesenteric artery. The potentiation can be interpreted in terms of inhibition of kininase 11 by captopril.
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The difference in potentiation by captopril of the algogenic action of bradykinin injected into the two arteries may reflect the difference in kininase 11 activity in the two arterial beds. Possible involvement of E-series prostaglandins in the potentiation was also discussed.
D-3-mercapto-2-methylpropanoyl-L-proline
(SQ 14,225 or captopril) is an orally active inhibitor of angiotensin I converting enzyme developed in the hope of its being useful in the diagnosis and treatment of patients with renin-dependent hypertension (1) (2) (3) . SQ 14, 225 is capable of producing a sustained fall of blood pressure in renin-dependent models of hypertension (4, 5) . Since angiotensin I converting enzyme also inactivates bradykinin as kininase 11 (6) , SQ 14, 225 augments the vasodepressor effect of intravenous bradykinin (1) (2) (3) . This is true for the vasodilator effects of bradykinin or kallikrein injected intra-arterially (7).
Thus, it can be anticipated that SQ 14,225 administered systemically would augment the algogenic effect of bradykinin. The present experiments were performed to elucidate this point. Since different mechanisms have been proposed to operate in the algogenic action of bradykinin in the hind limb (a somatic area) and in the gut (a visceral area) (8) experiments
were conducted in the two areas. Vocalization of conscious dogs to intra-arterial injection of algogenic substances is taken to reflect the algogenic action of these substances.
MATERIALS AND METHODS
Experiments were performed on 11 mongrel dogs of either sex, weighing 6-8 kg.
Polyvinyl tubing of about 0.6 mm in outer diameter was implanted in the femoral artery or in a branch of the ileal or jejunal (called simply mesenteric bellow) artery under pentobar bitone anaesthesia 4 or 5 days prior to the experiment. During the experiment the animals were loosely restrained with a hammock. Vocalization was picked up with a non-directional microphone placed about 30 cm in front of the nostril of the animal, and recorded on magnetic tapes. Throughout the experiment vocalization was simultaneously displayed as an integrated tracing through an RC circuit with a time constant of 2 sec. Details of the technique of implantation of the arterial catheter and experimental procedures were described previously (8, 9) . The compounds used were acetylcholine (ACh) chloride (Daiichi Seiyaku) All values are given in terms of mean+S.E., unless otherwise stated. Significance in differences between mean values was evaluated by Student's t-test, and expressed as p values.
The difference was judged to be significant when the p value was less than 0.05.
RESULTS
Since in dogs 1 mg/kg, i.v. of SQ 14,225 is known to be sufficient to potentiate the vasodilator effect of intra-arterial bradykinin on the vascular bed of the tongue (7), this dose was chosen in the experiments described below. In control experiments on the 5 dogs, the mean threshold dose of bradykinin for vocalization was 2.1 ±0.5 nmol (n=5).
In each dog a subthreshold dose for vocalization was chosen as a test dose and it was confirmed to be subthreshold for vocalization before administration of SQ 14,225 (Fig. 1) . The test dose was injected into the femoral artery 3-5 min after a single injection of SQ 14,225 (1 mg/kg, i.v.). As shown in Fig. 1 , the subthreshold test dose The potentiating effect of SQ 14,225 spared the algogenic action of ACh in both the hind limb and the gut. Thus, the mechanism for potentiation by SQ 14,225 of the algogenic action of bradykinin appears to be similar to that for potentiation by the same compound of the vasodepressor (1-3) or the vasodilator effect (7) of bradykinin. The proposed mecha nism is that exogenous bradykinin is less inactivated and remains in high concentrations at its site of action because kininase II which inactivates bradykinin is inhibited by SQ 14,225.
Kininase II and angiotensin I converting enzyme have been identified to be the same enzyme (6) . However, the possibility that a part of the potentiating effect of SQ 14,225 might be due to the enhanced release of E-series prostaglandins cannot be ruled out. It is known that bradykinin releases E-series prostaglandins from tissues (10) (11) (12) and that E-series prostaglandins sensitize endings of pain fibres in somatic (12, 13) and visceral areas (11, 13) .
In the presence of SQ 14,225 E-series prostaglandins are released in accordance with the remaining levels of bradykinin and the endings of pain fibres are sensitized accordingly. However, another explanation appears to be more plausible; the disparity may reflect the difference in the activity of kininase II in the two areas.
In the mesenteric arterial bed, kininase II activity just may be greater than in the femoral arterial bed. However, since there are no data comparing the activity of kininase II in the two arterial beds, the validity of our explanation awaits further experimental tests. It should be noted, however, that the angiotensin I converting enzyme activity of the femoral artery is lower than that of the coeliac artery which supplies the upper abdominal viscera (14) . In the preceding paragraph it was suggested that E-series prostaglandins released by bradykinin might also contribute to the potentiating effect of SQ 14,225. If such is indeed the case, the difference in release of E-series prostaglandins may also explain the dissimilarity in the potentiating effect of SQ 14,225 on the algogenic action of bradykinin.
The present results also suggest that SQ 14,225 may potentiate pathological pain in acute inflammation since the involvement of kinins (including bradykinin) has been suggested (15) , and if so augmentation of the algogenic action by SQ 14,225 would be less in the somatic area than in the visceral area. Alternatively, if SQ 14,225 fails in this regard, the involve ment of kinins in pathological pain in acute inflammation should be ruled out.
